Turner, Grace M.
McMullan, Christel
Aiyegbusi, Olalekan Lee
Hughes, Sarah E.
Walker, Anita
Jeyes, Felicity
Adler, Yvonne
Chong, Amy
Buckland, Lewis
Stanton, David
Davies, Elin Haf
Haroon, Shamil
Calvert, Melanie
Funding for this research was provided by:
National Institute for Health and Care Research (COV-LT-0013, COV-LT-0013, COV-LT-0013, COV-LT-0013, COV-LT-0013, COV-LT-0013, COV-LT-0013, COV-LT-0013, COV-LT-0013, COV-LT-0013, COV-LT-0013, COV-LT-0013, COV-LT-0013)
Article History
Received: 15 December 2022
Accepted: 22 March 2023
First Online: 30 March 2023
Declarations
:
: Ethical approval for the consensus workshop and feasibility trial was granted by the West Midlands -Solihull Research Ethics Committee (REC reference 21/WM/0203). Ethical approval was not required for other co-production activities with the patient and public involvement and engagement (PPIE) group. Informed consent for participation was obtained from all subjects involved in the study when applicable.
: Not applicable.
: GMT receives funding from the National Institute for Health and Care Research (NIHR) and UK Research and Innovation (UKRI). CM receives funding from NIHR Surgical Reconstruction and Microbiology Research Centre (SRMRC), UKRI, and declares personal fees from Aparito Ltd outside the submitted work. SEH receives funding from the NIHR Oxford-Birmingham Blood and Transplant Research Unit (BTRU) in Precision Cellular Therapeutics, NIHR ARC West Midlands at the University of Birmingham, UK SPINE and UKRI. SEH has received personal fees from Cochlear Ltd, Astra Zeneca, ICON, and Aparito Ltd outside the submitted work. OLA receives funding from the National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre, NIHR ARC West Midlands at the University of Birmingham, the Brain Tumour Charity, Innovate UK (part of UK Research and Innovation), Gilead Sciences Ltd. and Janssen Pharmaceuticals Inc. OLA declares personal fees from Gilead Sciences Ltd., GlaxoSmithKline (GSK) and Merck outside the submitted work. MJC is a NIHR Senior Investigator, receives funding from the NIHR Birmingham Biomedical Research Centre, NIHR Surgical Reconstruction and Microbiology Research Centre, NIHR Birmingham-Oxford Blood and Transplant Research Unit (BTRU) in Precision Transplant and Cellular Therapeutics, and NIHR ARC West Midlands at the University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, Health Data Research UK, Innovate UK (part of UK Research and Innovation), Macmillan Cancer Support, European Regional Development Fund—Demand Hub, SPINE UK, UKRI, UCB Pharma, GSK and Gilead Sciences. MJC receives personal fees from Astellas, Aparito Ltd, CIS Oncology, Takeda, Merck, Daiichi Sankyo, Glaukos, GSK, ICON and the Patient-Centered Outcomes Research Institute (PCORI) outside the submitted work. In addition, a family member owns shares in GSK. SH receives funding from the National Institute for Health and Care Research (NIHR) and UK Research and Innovation (UKRI).